Présentation de l'entreprise
Cue Biopharma, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing a novel class of injectable therapeutics designed to selectively engage and modulate targeted, disease-relevant T cells within the United States market. The company functions within the healthcare sector, specifically inside the biotechnology industry, where it focuses on advancing early-stage drug candidates rather than commercializing mature pharmaceutical products. As of the latest data, the firm maintains a market capitalization of $26.74M, generates annual revenue of $27.47M, and employs a workforce of 29 individuals. These valuation and revenue figures indicate that Cue Biopharma occupies a small-cap position in the biotechnology landscape, reflecting the typical scale of clinical-stage companies that prioritize research and development expenditures over immediate profitability or massive revenue generation.
Santé financière
The company reported revenue of $27.47M for the trailing twelve months, yet this revenue generated a net income of -$26,602,000 and an EBITDA of -$25,563,000, revealing a significant cost structure where operating expenses substantially exceed current revenue streams. The free cash flow stands at -$9,951,750, which indicates that the company is consuming cash reserves to fund its clinical development pipeline rather than generating positive cash flow from operations. Profitability metrics further illustrate this financial reality, with a gross margin of -26.9%, an operating margin of 8.9%, and a profit margin of -96.9%, suggesting that while operating costs are high, the company has managed to maintain a positive operating margin despite substantial losses on the bottom line. On the balance sheet, Cue Biopharma holds $28.23M in cash against $4.20M in debt, resulting in a debt-to-equity ratio of 15.88, which suggests a highly leveraged financial structure relative to its equity base despite the positive cash position. Liquidity is supported by a current ratio of 2.74, indicating that the company possesses sufficient short-term assets to cover its current liabilities with a comfortable buffer. Return on equity is recorded at -121.1% and return on assets at -44.6%, metrics that reveal that management is currently destroying shareholder value through significant accumulated losses rather than generating returns on the capital invested.
Évaluation de la valorisation
Valuation multiples for the company present a complex picture, with a trailing P/E ratio that is not applicable due to negative earnings and a forward P/E of -0.57, implying that the market prices the stock based on future earnings expectations that have not yet materialized in current results. The price-to-book ratio is 1.00, indicating that the market values the company at a level roughly equivalent to its book value, which is common for early-stage biotechs where intangible assets like drug candidates are not fully reflected on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 0.97 and an EV/EBITDA of -0.11, suggesting that the market is willing to pay slightly less than one dollar of equity value for every dollar of sales, reflecting a high-risk premium associated with the clinical stage of the business. The stock has exhibited significant volatility over the past year, trading between a 52-week high of $1.03 and a 52-week low of $0.17, placing the current trading price somewhere within this wide range and highlighting the speculative nature of the investment. The beta of 1.58 demonstrates that the stock is 58% more volatile than the broader market, meaning price swings will likely be more pronounced during periods of market stress or rally.
Growth & Income
Revenue growth for the trailing twelve months is an extraordinary 1292.3%, likely driven by the addition of new commercial entities or acquisitions, while earnings growth is not applicable due to the company's consistent losses, indicating that revenue expansion has not yet translated into profit generation. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash flow is being reinvested into research and development activities rather than distributed to shareholders. Since the earnings growth metric is unavailable and the company is in a cash-burning phase, the lack of a payout ratio suggests that the firm is prioritizing capital allocation toward achieving clinical milestones over providing income to investors. The overall growth and income profile characterizes Cue Biopharma as a high-risk, high-volatility asset suitable for portfolios seeking exposure to clinical-stage biotechnology innovation rather than current income or established profitability.